Effects of PPARg agonist pioglitazone on rat hepatic fibrosis

doi:10.3748/wjg.v10.i7.1047

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2570)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

310

HTML

1998

Figures (1-4)

120

Tables (1-3)

142

Sum=2570

Apr 1, 2004 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Apr 1, 2004; 10(7): 1047-1051
Published online Apr 1, 2004. doi: 10.3748/wjg.v10.i7.1047

Table 1 Effects of pioglitazone on liver inflammation and fibrosis scores (mean ± SD)

Group	n	Necroinflammatory scores	Fibosis scores
Control	10	0	0
Model	8	4.88 ± 2.30	7.00 ± 3.21
PI	10	2.80 ± 1.03^b	3.40 ± 1.65^b
PII	10	3.00 ± 1.05^a	4.60 ± 1.35^a

^aP < 0.05,

^bP < 0.01 vs model group.

Table 2 Effects of pioglitazone on liver functions in fibrotic rats (mean ± SD)

Group	n	ALT (U/L)	AST (U/L)
Control	10	41.09 ± 6.58	136.34 ± 31.23
Model	8	105.00 ± 23.71^d	397.86 ± 67.32^d
PI	10	58.64 ± 11.40^b	259.58 ± 45.89^b
PII	10	87.32 ± 15.65^a	344.49 ± 28.10^a

^aP < 0.05,

^bP < 0.01 vs model group;

^dP < 0.001 vs control group.

Table 3 Effects of pioglitazone on serum fibrotic markers in fibrotic rats (mean ± SD)

Group	n	HA (μg/L)	LN (μg/L)	PCIII (μg/L)
Control	10	57.75 ± 11.34	35.68 ± 6.02	85.94 ± 10.15
Model	8	167.64 ± 19.46^d	74.35 ± 12.45^d	178.93 ± 7.42^d
PI	10	71.25 ± 15.78^b	40.28 ± 9.91^b	149.23 ± 11.13^b
PII	10	103.64 ± 27.55^b	56.62 ± 8.95^b	161.30 ± 9.22^a

^aP < 0.05,

^bP < 0.01 vs model group;

^dP < 0.001 vs control group.

Citation: Yuan GJ, Zhang ML, Gong ZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004; 10(7): 1047-1051
URL: https://www.wjgnet.com/1007-9327/full/v10/i7/1047.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i7.1047